Ongoing Clinical Trials

Focal Segmental Glomerulosclerosis (FSGS)

Focal Segmental Glomerulosclerosis (FSGS)

A Randomized, Multicenter, Double-blind, Parallel, Active-control Study of the Effects of Sparsentan, a Dual Endothelin Receptor and Angiotensin Receptor Blocker, on Renal Outcomes in Patients With Primary Focal Segmental Glomerulosclerosis (FSGS).

ClinicalTrials.gov
Identifier: NCT03493685

Phase 3 trial

Principal Investigator

Michelle Rheault, MD

Study Coordinator

TBD


A Randomized, Double-Blind, Placebo-Controlled Dose-Ranging Study to Evaluate the Safety and Efficacy of CCX140-B in Subjects With Focal Segmental Glomerulosclerosis(FSGS).

ClinicalTrials.gov
Identifier: NCT03536754

Phase 2

Principal Investigator

Patrick H. Nachman, MD

Study Coordinators

Charlotte Quinton, RN, BSN
quint003@umn.edu

Elizabeth Miller, RN, BAN, PHN, CCRC
mill7440@umn.edu


An Open Label, Intra-Subject Dose Escalation Study of CCX140-B in Subjects With Primary Focal Segmental Glomerulosclerosis (FSGS) and Nephrotic Syndrome

ClinicalTrials.gov
Identifier: NCT03703908

Phase 2 trial

Principal Investigator

Patrick H. Nachman, MD

Study Coordinators

Charlotte Quinton, RN, BSN
quint003@umn.edu

Elizabeth Miller, RN, BAN, PHN, CCRC
mill7440@umn.edu


An Open-Label Dose-Exploration Cohort Study Evaluating the Efficacy and Safety of Voclosporin in Achieving Complete or Partial Remission of Proteinuria in Subjects with Focal Segmental Glomerulosclerosis.

ClinicalTrials.gov
Identifier: NCT03598036

Phase 2

Principal Investigator

Patrick H. Nachman, MD

Study Coordinators

Charlotte Quinton, RN, BSN
quint003@umn.edu

Elizabeth Miller, RN, BAN, PHN, CCRC
mill7440@umn.edu

IgA Nephropathy

IgA Nephropathy

A Randomized, Double-blind, Placebo-Controlled Study to Evaluate Efficacy and Safety of Nefecon in Patients with Primary IgA (Immunoglobulin A) Nephropathy at Risk of Progressing to End-stage Renal Disease (NefIgArd).

ClinicalTrials.gov
Identifier: NCT03643965

Phase 3

Principal Investigator

Surabhi Thakar, MD

Study Coordinators

Charlotte Quinton, RN, BSN
quint003@umn.edu

Elizabeth Miller, RN, BAN, PHN, CCRC
mill7440@umn.edu


A Randomized, Double-blind, Placebo-controlled, Phase 3 Study of the Safety and Efficacy of OMS721 in Patients with Immunoglobulin A (IgA) Nephropathy (ARTEMIS - IGAN).

ClinicalTrials.gov
Identifier: NCT03608033

Phase 3

Principal Investigator

Patrick H. Nachman, MD

Study Coordinators

Charlotte Quinton, RN, BSN
quint003@umn.edu

Elizabeth Miller, RN, BAN, PHN, CCRC
mill7440@umn.edu